In developed countries, driven by poor diet and low exercise, fatty liver diseases have quietly reached epidemic levels across both adults and children. In the early stages, symptoms of liver disease are few, which is why the scale of the problem has gone largely unnoticed. With care the liver can heal itself, but without timely action liver damage can become permanent.

The economic impact of liver disease is enormous. For example, in the United States approximately 30% of US adults and as many as 1 in 10 children suffer from some form of liver disease, leading to direct and societal costs estimated at almost $300B per year. There is therefore an acute need for earlier detection when lifestyle changes and therapeutics can be effectively deployed, and the number of patients experiencing severe symptoms reduced.

• POSTER: Pre-clinical in vitro VOC analysis to identify biomarker candidates for chronic liver diseases detection – A Breath Biopsy study.
• PAPER: Targeted breath analysis: exogenous volatile organic compounds (EVOC) as metabolic pathway-specific probes
• PAPER: VOCs from Exhaled Breath for the Diagnosis of Hepatocellular Carcinoma
• PAPER: Optimization of a breath analysis methodology to potentially diagnose transplanted kidney rejection
• PAPER: A deep learning approach for detecting liver cirrhosis from volatolomic analysis of exhaled breath
• PAPER: Visualization of exhaled breath metabolites reveals distinct diagnostic signatures for acute cardiorespiratory breathlessness
• REVIEW: Could breath acetone be a potentially useful biomarker for heart failure?
• POSTER: Comparing cirrhosis and liver cancers – A Breath Biopsy study with Cleveland Clinic proposing ketones and terpenes as possible biomarkers of chronic liver diseases